Over time, the medical environment has witnessed several happenings that point to an interesting shift in the way patients are monitored. Of late, patients now wear smartwatches that quietly track heart rate variability and oxygen saturation throughout the day. Others rely on a continuous glucose monitor that sends metabolic data to a smartphone in real time. Someone else sleeps with a ring that records temperature, respiratory rate, and patterns of sleep. In intensive care units, patients generate vast streams of physiological data every minute. At the same time, fertility applications estimate ovulation windows, while mental health platforms attempt to detect early signs of distress through speech patterns or typing behavior. The most notable being that artificial intelligence systems now heavily depend on these continuous streams of biological data to make predictions about disease, performance, and risk.
Despite all this, medicine is still often understood as something episodic. Something of a cycle in which a patient develops symptoms, consults a physician, receives treatment, and returns to everyday life. Unfortunately, that understanding is becoming harder to sustain. What we have instead is a model of care built around the continuous observation of the human body, where data is generated not only in clinics and hospitals, but throughout the ordinary phases of daily life.
Notably, the technology driving this shift has advanced quickly and, in many cases, quietly. On the other hand, the legal and ethical frameworks that should guide its use have not kept pace, and this gap has begun to produce real and consequential risks.
At first glance, the idea of “human-biology telemetry regulation” may seem like a technical concern, confined to specialists in health law or biomedical engineering. But, in practice, it touches on much broader questions that are rapidly becoming unavoidable. It is no longer simply a matter of whether the human body can be measured continuously. From all indications, that question has already been answered. What remains unsettled is how those measurements are governed. Who controls the data generated by these devices? Who is responsible for interpreting it, and under what standard? Who benefits economically from its use? And when something goes wrong, probably when a signal is missed, misinterpreted, or ignored, where does liability fall?
Real physician voices, twice a week
Free, and one click to unsubscribe.
At present, there is no clear or consistent framework for answering these questions. The boundary between consumer technology and regulated medical practice remains indistinct, and that uncertainty creates exposure not only for patients, but also for clinicians, institutions, and the companies developing these systems.
The gray areas of continuous monitoring
As mentioned earlier, the rise of continuous telemetry introduces a level of uncertainty that sits uneasily with existing legal standards. Traditionally, a physician’s responsibility has been tied to the information available within a defined clinical encounter. A patient presents, an assessment is made, and decisions follow from what is known at that point in time. However, continuous monitoring complicates this structure. This is because when physiological data is being generated around the clock, it becomes less clear where the boundaries of responsibility begin and end.
If a patient’s data reveals concerning trends outside of a scheduled interaction, is there an obligation to act on it? And if so, who bears that responsibility? It could be the treating physician, the hospital system, the manufacturer of the device, the software platform that processes the data, or a third-party service tasked with monitoring it.
The difficulty is compounded by the way legal standards tend to develop. In many areas of medicine, expectations are defined retrospectively, often in response to adverse outcomes. A very good example would be the experience had with electronic medical records. These systems were introduced with the promise of improving efficiency and reducing error. Indeed, they have delivered certain benefits. But they have also transformed clinical documentation into a detailed and permanent record of decision-making. Time stamps, unread alerts, and system logs now form part of key evidence in malpractice claims, and clinicians have had to adjust to a new kind of scrutiny.
Continuous telemetry has the potential to extend this dynamic considerably. Rather than focusing on discrete encounters, future disputes may involve the retrospective examination of long stretches of physiological data, with attention directed toward patterns that, in hindsight, appear significant. It is not difficult to imagine how such a scenario might unfold. A clinician could be asked to account for trends, maybe gradual changes in heart rate, oxygen levels, sleep patterns, or activity, that unfolded over days or weeks. Even where the clinician never had access to that information, the expectation that someone should have been monitoring it may begin to take hold, quietly reshaping what is considered reasonable care.
Could more data create more liability
There is an intuitive appeal to the idea that more data leads to better outcomes. Earlier detection, more precise monitoring, and predictive analytics all suggest a future in which deterioration is identified before it becomes critical. But the relationship between data and care is not as straightforward.
Some scholars argue that health systems are already struggling with the volume of information they must process. They further argue that clinicians always must address large numbers of alerts and notifications, many of which carry limited clinical significance. As such, introducing continuous streams of patient-generated data into this environment risks adding to an already substantial burden.
Besides, the challenge is not only technical, but practical. Data, on its own, does not improve care; it must be filtered, interpreted, and acted upon. Consequently, without clear systems for prioritization, adequate staffing, and well-defined escalation pathways, the sheer volume of information can obscure rather than clarify what matters.
This raises an important question about capacity. No clinical workforce can reasonably be expected to monitor continuous physiological streams without structural support. Yet, in many instances, telemetry technologies are being introduced more rapidly than the systems required to manage them effectively.
The blurred boundary between wellness and medicine
The distinction between medical care and consumer wellness has become progressively harder to define. Arguably, medical devices were once confined to regulated clinical settings. However, many of today’s technologies are designed for direct consumer use. They are often framed in the language of wellness, even when their functions closely resemble those of diagnostic tools. A smartwatch may stop short of claiming that it detects disease yet still suggest that it can identify potentially serious conditions. Similarly, applications that track sleep or stress may avoid clinical terminology while producing outputs that users interpret as medical assessments. This creates a space in which expectations can outpace regulation.
Accordingly, consumers may come to rely on these systems as if they were subject to the same standards as clinical devices, even when that is not the case. Clinicians, in turn, are often left to respond to the consequences, whether in the form of false alarms, incidental findings, or heightened patient anxiety.
The effects are already visible. Patients increasingly present to clinical settings after receiving alerts from wearable devices. Some of these alerts are clinically meaningful; others are not. Regardless, once continuous monitoring becomes normalized, the demand for explanation increases. Patients begin to expect clarity and precision for variations that may, in many cases, fall within the normal range of human physiology.
That expectation can be difficult to meet. It is no news that the human body is not a static system; it fluctuates constantly, and so not every change signals disease. At the same time, many telemetry-based platforms are designed in ways that encourage ongoing engagement. Notifications prompt attention, continuous tracking reinforces usage, and large-scale data collection supports the development of predictive algorithms. It is important to mention at this point that these design choices are not incidental. They reflect an underlying economic model. As such, it will be right to argue that human-biological telemetry, in this sense, is not only a development in health care. It is also part of a rapidly expanding data economy that raises important questions about incentives, oversight, and control.
The risks of biologic data
Biologic data is quickly becoming one of the most valuable commodities of the coming decade. Unlike passwords or credit card details, it is not something that can be reset or replaced once exposed. The signals it captures, like heart rhythms, gait patterns, vocal signatures, retinal scans, genomic profiles, and behavioral markers, reveal a lot. From them, it is increasingly possible to infer illness, emotional states, reproductive health, cognitive decline, susceptibility to addiction, and broader patterns of mental vulnerability.
What makes this especially concerning is that much of this information appears, on the surface, harmless. A step count, a sleep score, or a heart rate trend rarely feels sensitive in isolation. Yet, when aggregated and analyzed over time, these data points can produce remarkably detailed portraits of individual health and behavior. This happens often in ways that users neither anticipate nor fully understand.
The regulatory environment governing this space has not kept pace with its expansion. Existing frameworks, such as HIPAA, were designed for a very different model of care centered on clinical encounters and institutional record-keeping. Today, a significant portion of biologic data is generated outside those settings, through consumer devices and platforms that may fall beyond traditional health privacy protections. Whether that data is protected often depends less on its sensitivity and more on how it is collected, stored, or classified.
This creates a precarious situation. Patients frequently assume that their biologic data is protected in the same way as hospital records, when in many cases it is not. That misunderstanding introduces significant levels of legal ambiguity and ethical risk.
At the same time, the incentives surrounding this data are expanding. Insurance companies, employers, advertisers, and data brokers all stand to benefit from access to predictive biologic information. Accordingly, the implications of that access are difficult to ignore.
If insurers can detect physiological patterns associated with future chronic illness before a diagnosis is formally made, how might that shape coverage decisions? If employers begin to rely on fatigue metrics or stress indicators as proxies for productivity, what becomes of employee autonomy? If predictive analytics can identify mental health vulnerability before individuals themselves recognize it, how is that information used, and by whom?
In such a landscape, the distinction between health optimization and biologic surveillance becomes increasingly difficult to sustain. It is for this reason that human-biology telemetry regulation cannot remain a peripheral concern.
Four regulatory priorities that should be adopted
If the field is to develop responsibly, it requires a set of coherent principles that can guide its growth before market forces alone determine its boundaries.
The first priority is the question of ownership. Individuals should retain meaningful control over the continuous physiological data generated by their own bodies. Consent, as it currently exists in many digital ecosystems, is often buried within lengthy and opaque user agreements that few read and even fewer fully understand. That model is inadequate for data of this sensitivity. At a minimum, individuals should have clear visibility into who can access their data, how long it is retained, whether it may be sold or shared, and how it is used in training predictive systems.
The second priority concerns the distinction between wellness technologies and medical technologies. That boundary, which was once relatively clear, has become increasingly blurred. Where a device meaningfully shapes medical decision-making, whether by triggering alerts, prompting clinical visits, or influencing treatment choices, it cannot reasonably exist outside meaningful regulatory scrutiny. It is no longer sufficient for companies to rely on carefully worded disclaimers while simultaneously exerting real clinical influence over users’ decisions.
The third priority lies within health systems themselves. Continuous monitoring introduces ambiguity around responsibility, particularly when escalation pathways are not clearly defined. Institutions must establish explicit protocols that determine who reviews telemetry data, when that review occurs, what thresholds warrant intervention, and how responsibility is transferred across teams. Without such structures, clinicians risk inheriting obligations that are neither clearly defined nor realistically manageable.
Moreover, there is a persistent assumption that more data naturally leads to better outcomes. In practice, the opposite can occur. Poorly governed telemetry systems can generate confusion, drive defensive medical practices, increase unnecessary testing, and contribute to both alert fatigue and workforce burnout. In such environments, the signals that truly matter may be delayed or overlooked. Data only improves care when the systems surrounding it are designed to manage it effectively.
The fourth priority is algorithmic transparency. Many telemetry platforms now rely on artificial intelligence to generate predictions, alerts, and risk assessments. Yet the processes behind these outputs are usually opaque and unclear, leaving both clinicians and patients with limited insight into how conclusions are reached.
This opacity creates a fundamental problem of accountability. If an algorithm fails to detect early sepsis, misjudges arrhythmia risk, or produces biased outputs across different populations, responsibility becomes difficult to assign. Does it lie with the physician who relied on the system, the institution that implemented it, the engineers who developed it, or the company that deployed it?
The normalization of biologic surveillance
The implications of telemetry extend well beyond traditional health care settings. Military organizations, athletic programs, educational institutions, correctional systems, and workplaces are all exploring ways to incorporate biologic monitoring into their operations. In some contexts, these applications may enhance safety or performance. In others, they risk normalizing forms of surveillance that would previously have been considered intrusive.
History offers repeated examples of technologies introduced for beneficial purposes gradually expanding beyond their original scope. Biologic telemetry may follow a similar trajectory, in part because it appears so benign at the outset. A fitness tracker feels harmless; a sleep score appears useful; a stress index seems empowering. Yet, over time, the accumulation of such tools can change the expectations of the users.
Furthermore, as continuous monitoring becomes more common, opting out may become less straightforward. Individuals who decline participation could begin to be perceived, subtly or explicitly, as less responsible, less compliant, or higher risk. At the same time, the very notion of what constitutes “normal” may begin to narrow, defined increasingly by quantified benchmarks rather than broader understandings of human variation.
The philosophical aspect of telemetry
There is also a deeper tension within telemetry-driven medicine which is not necessarily technical or legal, but philosophical. Ideally, not every aspect of human health can be meaningfully reduced to data. Experiences such as suffering, resilience, cognition, uncertainty, and healing do not always lend themselves to continuous measurement. Admittedly, physiologic signals can provide valuable insight, but they cannot fully capture the complexity of human experience.
There is a risk that, in prioritizing what can be measured, medicine may begin to overlook what cannot. Patients may come to be seen less as individuals and more as collections of data points, like streams of signals to be analyzed, categorized, and predicted.
It is important to admit that acknowledging this limitation does not diminish the value of telemetry. On the contrary, its potential is substantial. Continuous cardiac monitoring can detect life-threatening arrhythmias; glucose sensors have transformed diabetes care; early warning systems may improve the detection of sepsis; and advances in neurologic monitoring may eventually allow for earlier identification of cognitive decline. The issue is not whether these technologies are useful. It is that innovation, when introduced without adequate governance, often produces consequences that are only understood in retrospect.
The question, then, is not whether biologic telemetry should exist. It already does, and its role will only expand. What remains uncertain is whether regulatory frameworks can evolve quickly enough to preserve patient autonomy, protect clinicians from unmanageable liability, and maintain public trust before commercial incentives come to dominate the landscape.
We are entering a period in which the boundaries between medicine, consumer technology, employment, insurance, and behavioral analytics are becoming increasingly porous. For now, it may still seem like a specialized concern. But in time, it is likely to become foundational.
Overall, this trend has revealed that the most valuable resource in the future of medicine may not be infrastructure, pharmaceuticals, or even clinical expertise, but the continuous stream of data generated by human life itself. If that reality is not carefully governed, the consequences will extend beyond privacy alone.
Chinmeri Nwuba is a health policy writer.
